Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:PFE

Pfizer Inc (PFE)

26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
0
TOP PICK
Best value in the market is in quality names. Best pharmaceutical company in the world. Just hasn't gone anywhere. New products are going into the pipeline.
PAST TOP PICK
(A Top Pick Dec 29/03. Down 9%.) Have bought more on the dips. Health care industry in the US has suffered for the last 2 years. Showing strong revenue growth.
BUY
A lot of drug stocks have been under pressure. All of the US drug companies are in a favorable position of having reasonable growth prospects.
DON'T BUY
Feels the US drug companies will continue to have tough sledding because of generics. This company is better equipped to fight that. Growth through acquisition.
TOP PICK
Best U.S. drug company. They have new products that were just introduced. Own Lipridor, the largest drug.
TRADE
Long-term: it is a good investment.
BUY
A lot of the US drug stocks got ahead of themselves for the last couple of years. Actually looks pretty good now. At about 20X earnings now.
DON'T BUY
This is one of those stocks which everyone loves. This means everyone owns it, which concludes no one will buy any more. It is in a negative trend.
BUY
Has the highest yield and lowest PE that it has had for many many years. Good product pipeline. The stocks and biotechnology will do well in this decade. Hold for 1 to 2 years.
TOP PICK
It has not been a good month for pharmaceuticals. US election is causing some uncertainty which has put some pressure on the stock. A world-class company. Good revenue growth. Looking at about 13 X 2005 earnings.
DON'T BUY
An excellent company, but there are other places they would rather invest in, such as Johnson and Johnson. Under attack by generic products.
DON'T BUY
Sector analysis indicates more distribution than new accumulation so in general, pharmaceuticals are underperforming. They were treated as defensive holdings during the bear market. Since then, earnings haven't been strong enough to sustain valuation.
BUY
A great name for a long-term holding. A more conservative guidance brought the stock down. Drug stocks tend to do best when interest rates are rising.
WEAK BUY
Like this sector. Good name. Growth potential is good.
TOP PICK
Likes the quality stocks, especially the health related ones.
Showing 631 to 645 of 801 entries